Literature DB >> 15673743

Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

C N Paramasivan1, S Sulochana, G Kubendiran, P Venkatesan, D A Mitchison.   

Abstract

The bactericidal activity of gatifloxacin, alone and in combination with isoniazid and rifampin, was studied on both exponential- and stationary-phase cultures of Mycobacterium tuberculosis strain H37Rv. On log-phase cultures, the bactericidal activity of gatifloxacin at 4 microg/ml was rapid and was very similar to that of isoniazid. At concentrations of 0.25 and 4 microg/ml, gatifloxacin enhanced the activity of isoniazid. Killing of the stationary-phase culture was biphasic. During the first 2 days, gatifloxacin at 4 microg/ml slightly increased the limited bactericidal activities of isoniazid and rifampin. However, no further additional bactericidal activity was found during further incubation with isoniazid alone or when gatifloxacin was added to either isoniazid or rifampin. This suggested that the stationary-phase culture contained a mixture of occasionally dividing bacilli that were killed during the first 2 days and true static persisters in the residual population that mimicked those in human lesions. In view of the failure of gatifloxacin to add to the sterilizing activity of isoniazid or rifampin during days 2 to 6 of exposure in the stationary-phase culture, it is unlikely to be a sterilizing drug that can be used to shorten the duration of treatment appreciably when it is added to present treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673743      PMCID: PMC547312          DOI: 10.1128/AAC.49.2.627-631.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

2.  Development of fluoroquinolones as first-line drugs for tuberculosis--at long last!

Authors:  Richard J O'Brien
Journal:  Am J Respir Crit Care Med       Date:  2003-12-01       Impact factor: 21.405

3.  Fluoroquinolones in the treatment of tuberculosis: a study in mice.

Authors:  Denis A Mitchison
Journal:  Am J Respir Crit Care Med       Date:  2004-02-01       Impact factor: 21.405

4.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  The bactericidal activities of antituberculous drugs.

Authors:  D A MITCHISON; J B SELKON
Journal:  Am Rev Tuberc       Date:  1956-08

6.  A selective oleic acid albumin agar medium for tubercle bacilli.

Authors:  D A Mitchison; B W Allen; L Carrol; J M Dickinson; V R Aber
Journal:  J Med Microbiol       Date:  1972-05       Impact factor: 2.472

Review 7.  Role of individual drugs in the chemotherapy of tuberculosis.

Authors:  D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2000-09       Impact factor: 2.373

8.  Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.

Authors:  Michael H Cynamon; Mary Sklaney
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

Authors:  A Jindani; A J Nunn; D A Enarson
Journal:  Lancet       Date:  2004 Oct 2-8       Impact factor: 79.321

10.  Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.

Authors:  Amina Jindani; Caroline J Doré; Denis A Mitchison
Journal:  Am J Respir Crit Care Med       Date:  2003-01-06       Impact factor: 21.405

View more
  22 in total

1.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Authors:  Griselda Tudó; Ken Laing; Denis A Mitchison; Philip D Butcher; Simon J Waddell
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

2.  Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.

Authors:  Geraint R Davies; Richard Brindle; Saye H Khoo; Leon J Aarons
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.

Authors:  Kristin N Adams; Kevin Takaki; Lynn E Connolly; Heather Wiedenhoft; Kathryn Winglee; Olivier Humbert; Paul H Edelstein; Christine L Cosma; Lalita Ramakrishnan
Journal:  Cell       Date:  2011-03-03       Impact factor: 41.582

Review 5.  Antituberculosis therapy for 2012 and beyond.

Authors:  Michael Lauzardo; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2012-02-15       Impact factor: 3.889

6.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12

Review 7.  New insights into TB physiology suggest untapped therapeutic opportunities.

Authors:  Christina E Baer; Eric J Rubin; Christopher M Sassetti
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

8.  Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.

Authors:  Dorothee Heemskerk; Jeremy Day; Tran Thi Hong Chau; Nguyen Huy Dung; Nguyen Thi Bich Yen; Nguyen Duc Bang; Laura Merson; Piero Olliaro; Thomas Pouplin; Maxine Caws; Marcel Wolbers; Jeremy Farrar
Journal:  Trials       Date:  2011-02-02       Impact factor: 2.279

Review 9.  Confronting the scientific obstacles to global control of tuberculosis.

Authors:  Douglas B Young; Mark D Perkins; Ken Duncan; Clifton E Barry
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 10.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.

Authors:  Clifton E Barry; Helena I Boshoff; Véronique Dartois; Thomas Dick; Sabine Ehrt; JoAnne Flynn; Dirk Schnappinger; Robert J Wilkinson; Douglas Young
Journal:  Nat Rev Microbiol       Date:  2009-10-26       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.